Brolucizumab wins FDA approval, introducing extended dosing for wet AMD

• Posted on: Oct 9 2019
• By: Saratoga Opthalmology
• Leave a response

Novartis’ brolucizumab (Beovu) is now FDA approved for the treatment of wet AMD, the company reported today.
Source: AAO

Posted in: Uncategorized